Open an account

Phio Pharmaceuticals

PHIO · NASDAQ

$0.8921+$0.0232 (+2.67%)TodayMarket closed ·
Prev close $0.8689

PHIO analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold0
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $14.28 (+1500.7% upside)

Low
$14.14
Now
$0.8921
High
$14.70

Upgrades and downgrades

The latest rating actions, newest first

PHIO analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 26, 2026MaintainsBuy
HC Wainwright & Co.Feb 10, 2026MaintainsBuy

The case for and against

Updated Dec 15, 2025

Bull case

Phio Pharmaceuticals Corp. benefits from its proprietary INTASYL self-delivering RNAi technology, which has the potential to effectively target proteins that impair the immune response against cancer, positioning the company for substantial growth in the biotechnology sector. Recent findings indicate that the administration of PH-762 has been well-tolerated across multiple cohorts, with no dose-limiting toxicities or significant adverse events reported, suggesting a promising safety profile. The potential for securing partnership agreements to advance its pipeline further enhances the company's outlook as it aims to establish PH-762 as a first-in-class therapeutic for treating various cancers.

Bear case

Phio Pharmaceuticals Corp faces significant challenges that negatively impact its financial outlook, primarily due to the risks associated with failed or inconclusive clinical trials, which could hinder the advancement of its therapeutics. Additionally, the company may struggle to secure sufficient funding to support product development, increasing the likelihood of dilutive capital raises that could diminish shareholder value. Furthermore, there are concerns regarding the potential for lack of commercial success and the associated risk of delisting, further complicating the company's financial stability and growth prospects.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.